Across TCGA pan-cancer cohorts, TMEM167B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TMEM167B data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher TMEM167B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM167B expression acts as an unfavorable survival marker.

CESC and SKCM are the cancer types where TMEM167B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.258	0.798	.005	12	view →
SKCM	DFS	Median	II,III,IV	0.198	0.682	.027	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TMEM167B tumor-vs-normal RNA expression · all TMEM167B data types